GoodRx Holdings (GDRX) Net Income towards Common Stockholders (2019 - 2026)

GoodRx Holdings' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at $1.2 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders fell 89.42% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $20.6 million (down 27.75% YoY), while the FY2025 annual figure was $30.4 million, up 85.72% from the prior year.
• Net Income towards Common Stockholders came in at $1.2 million for Q1 2026 at GoodRx Holdings, down from $5.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $58.8 million in Q2 2023 to a low of -$41.7 million in Q3 2022.
• A 5-year average of $370705.9 and a median of $1.2 million in 2026 frame the typical range for Net Income towards Common Stockholders.
• On a YoY basis, Net Income towards Common Stockholders climbed as much as 4254.49% in 2023 and fell as far as 1211.82% in 2023.
• GoodRx Holdings' Net Income towards Common Stockholders stood at -$2.0 million in 2022, then sank by 1211.82% to -$25.9 million in 2023, then jumped by 126.05% to $6.7 million in 2024, then fell by 19.51% to $5.4 million in 2025, then slumped by 78.45% to $1.2 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $1.2 million, $5.4 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison